Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

ICAM3-Fc Outperforms Receptor-Specific Antibodies Targeted Nanoparticles to Dendritic Cells for Cross-Presentation.

Cruz LJ, Tacken PJ, van der Schoot JMS, Rueda F, Torensma R, Figdor CG.

Molecules. 2019 May 12;24(9). pii: E1825. doi: 10.3390/molecules24091825.

2.

The Dilemma of Cure and Damage in Oligodendroglioma: Ways to Tip the Balance Away from the Damage.

Torensma R.

Cancers (Basel). 2018 Nov 12;10(11). pii: E431. doi: 10.3390/cancers10110431.

3.

Immune Curbing of Cancer Stem Cells by CTLs Directed to NANOG.

Wefers C, Schreibelt G, Massuger LFAG, de Vries IJM, Torensma R.

Front Immunol. 2018 Jun 19;9:1412. doi: 10.3389/fimmu.2018.01412. eCollection 2018.

4.

Different Lipid Regulation in Ovarian Cancer: Inhibition of the Immune System.

Wefers C, Duiveman-de Boer T, Zusterzeel PLM, Massuger LFAG, Fuchs D, Torensma R, Wheelock CE, de Vries IJM.

Int J Mol Sci. 2018 Jan 17;19(1). pii: E273. doi: 10.3390/ijms19010273.

5.

Umbilical cord blood CD34+ progenitor-derived NK cells efficiently kill ovarian cancer spheroids and intraperitoneal tumors in NOD/SCID/IL2Rgnull mice.

Hoogstad-van Evert JS, Cany J, van den Brand D, Oudenampsen M, Brock R, Torensma R, Bekkers RL, Jansen JH, Massuger LF, Dolstra H.

Oncoimmunology. 2017 May 11;6(8):e1320630. doi: 10.1080/2162402X.2017.1320630. eCollection 2017.

6.

Controlled release of antigen and Toll-like receptor ligands from PLGA nanoparticles enhances immunogenicity.

Cruz LJ, Tacken PJ, Eich C, Rueda F, Torensma R, Figdor CG.

Nanomedicine (Lond). 2017 Mar;12(5):491-510. doi: 10.2217/nnm-2016-0295. Epub 2017 Feb 9.

PMID:
28181470
7.

Expansion of a BDCA1+CD14+ Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines.

Bakdash G, Buschow SI, Gorris MA, Halilovic A, Hato SV, Sköld AE, Schreibelt G, Sittig SP, Torensma R, Duiveman-de Boer T, Schröder C, Smits EL, Figdor CG, de Vries IJ.

Cancer Res. 2016 Aug 1;76(15):4332-46. doi: 10.1158/0008-5472.CAN-15-1695. Epub 2016 Jun 20.

8.

The European antibody network's practical guide to finding and validating suitable antibodies for research.

Roncador G, Engel P, Maestre L, Anderson AP, Cordell JL, Cragg MS, Šerbec VČ, Jones M, Lisnic VJ, Kremer L, Li D, Koch-Nolte F, Pascual N, Rodríguez-Barbosa JI, Torensma R, Turley H, Pulford K, Banham AH.

MAbs. 2016;8(1):27-36. doi: 10.1080/19420862.2015.1100787. Epub 2015 Sep 29.

9.

Humoral and cellular immune responses after influenza vaccination in patients with postcancer fatigue.

Prinsen H, van Laarhoven HW, Pots JM, Duiveman-de Boer T, Mulder SF, van Herpen CM, Jacobs JF, Leer JW, Bleijenberg G, Stelma FF, Torensma R, de Vries IJ.

Hum Vaccin Immunother. 2015;11(7):1634-40. doi: 10.1080/21645515.2015.1040207.

10.

Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence.

Wefers C, Lambert LJ, Torensma R, Hato SV.

Gynecol Oncol. 2015 May;137(2):335-42. doi: 10.1016/j.ygyno.2015.02.019. Epub 2015 Feb 26. Review.

PMID:
25727651
11.

Lithium inhibits palatal fusion and osteogenic differentiation in palatal shelves in vitro.

Meng L, Wang X, Torensma R, Von den Hoff JW, Bian Z.

Arch Oral Biol. 2015 Mar;60(3):501-7. doi: 10.1016/j.archoralbio.2014.12.011. Epub 2014 Dec 18.

PMID:
25555252
12.

Restoring immunosurveillance by dendritic cell vaccines and manipulation of the tumor microenvironment.

Vasaturo A, Verdoes M, de Vries J, Torensma R, Figdor CG.

Immunobiology. 2015 Feb;220(2):243-8. doi: 10.1016/j.imbio.2014.11.007. Epub 2014 Nov 15. Review.

PMID:
25466585
13.

Cord blood mesenchymal stem cells suppress DC-T Cell proliferation via prostaglandin B2.

van den Berk LC, Jansen BJ, Snowden S, Siebers-Vermeulen KG, Gilissen C, Kögler G, Figdor CG, Wheelock CE, Torensma R.

Stem Cells Dev. 2014 Jul 15;23(14):1582-93. doi: 10.1089/scd.2013.0433. Epub 2014 Apr 23.

14.

Aiming to immune elimination of ovarian cancer stem cells.

Di J, Duiveman-de Boer T, Figdor CG, Torensma R.

World J Stem Cells. 2013 Oct 26;5(4):149-62. doi: 10.4252/wjsc.v5.i4.149. Review.

15.

Wnt16 is involved in intramembranous ossification and suppresses osteoblast differentiation through the Wnt/β-catenin pathway.

Jiang Z, Von den Hoff JW, Torensma R, Meng L, Bian Z.

J Cell Physiol. 2014 Mar;229(3):384-92. doi: 10.1002/jcp.24460.

PMID:
24037946
16.

The stem cell markers Oct4A, Nanog and c-Myc are expressed in ascites cells and tumor tissue of ovarian cancer patients.

Di J, Duiveman-de Boer T, Zusterzeel PL, Figdor CG, Massuger LF, Torensma R.

Cell Oncol (Dordr). 2013 Oct;36(5):363-74. doi: 10.1007/s13402-013-0142-8. Epub 2013 Aug 9.

PMID:
23928726
17.

Functional OCT4-specific CD4+ and CD8+ T cells in healthy controls and ovarian cancer patients.

Di J, Massuger LF, Duiveman-de Boer T, Zusterzeel PL, Figdor CG, Torensma R.

Oncoimmunology. 2013 May 1;2(5):e24271. Epub 2013 Apr 1.

18.

The multiple faces of prostaglandin E2 G-protein coupled receptor signaling during the dendritic cell life cycle.

De Keijzer S, Meddens MB, Torensma R, Cambi A.

Int J Mol Sci. 2013 Mar 25;14(4):6542-55. doi: 10.3390/ijms14046542. Review.

19.

Humoral and cellular immune responses after influenza vaccination in patients with chronic fatigue syndrome.

Prinsen H, de Vries IJ, Torensma R, Pots JM, Mulder SF, van Herpen CM, Elving LD, Bleijenberg G, Stelma FF, van Laarhoven HW.

BMC Immunol. 2012 Dec 17;13:71. doi: 10.1186/1471-2172-13-71.

20.

Enhancing immunogenicity and cross-reactivity of HIV-1 antigens by in vivo targeting to dendritic cells.

Cruz LJ, Rueda F, Tacken P, Albericio F, Torensma R, Figdor CG.

Nanomedicine (Lond). 2012 Oct;7(10):1591-610. doi: 10.2217/nnm.12.131. Review.

PMID:
23148541
21.

The impact of cell source, culture methodology, culture location, and individual donors on gene expression profiles of bone marrow-derived and adipose-derived stromal cells.

Torensma R, Prins HJ, Schrama E, Verwiel ET, Martens AC, Roelofs H, Jansen BJ.

Stem Cells Dev. 2013 Apr 1;22(7):1086-96. doi: 10.1089/scd.2012.0384. Epub 2012 Dec 21.

22.

Quantifying the efficacy of influenza vaccines.

Torensma R.

Lancet Infect Dis. 2012 Sep;12(9):656; author reply 660-1. doi: 10.1016/S1473-3099(12)70135-4. No abstract available.

PMID:
22917094
23.

Deciphering the message broadcast by tumor-infiltrating dendritic cells.

Karthaus N, Torensma R, Tel J.

Am J Pathol. 2012 Sep;181(3):733-42. doi: 10.1016/j.ajpath.2012.05.012. Epub 2012 Jul 13. Review.

24.

Matrigel, but not collagen I, maintains the differentiation capacity of muscle derived cells in vitro.

Grefte S, Vullinghs S, Kuijpers-Jagtman AM, Torensma R, Von den Hoff JW.

Biomed Mater. 2012 Oct;7(5):055004. doi: 10.1088/1748-6041/7/5/055004. Epub 2012 Jul 13.

PMID:
22791687
25.

Mesenchymal stem cell-conditioned medium accelerates regeneration of human renal proximal tubule epithelial cells after gentamicin toxicity.

Moghadasali R, Mutsaers HA, Azarnia M, Aghdami N, Baharvand H, Torensma R, Wilmer MJ, Masereeuw R.

Exp Toxicol Pathol. 2013 Jul;65(5):595-600. doi: 10.1016/j.etp.2012.06.002. Epub 2012 Jun 21.

26.

Antibodies and carbohydrate ligands binding to DC-SIGN differentially modulate receptor trafficking.

Tacken PJ, Ter Huurne M, Torensma R, Figdor CG.

Eur J Immunol. 2012 Aug;42(8):1989-98. doi: 10.1002/eji.201142258.

27.

Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN.

Cruz LJ, Tacken PJ, Pots JM, Torensma R, Buschow SI, Figdor CG.

Biomaterials. 2012 Jun;33(16):4229-39. doi: 10.1016/j.biomaterials.2012.02.036. Epub 2012 Mar 10.

PMID:
22410170
28.

Harnessing human plasmacytoid dendritic cells as professional APCs.

Tel J, van der Leun AM, Figdor CG, Torensma R, de Vries IJ.

Cancer Immunol Immunother. 2012 Aug;61(8):1279-88. Review.

29.

Myogenic capacity of muscle progenitor cells from head and limb muscles.

Grefte S, Kuijpers MA, Kuijpers-Jagtman AM, Torensma R, Von den Hoff JW.

Eur J Oral Sci. 2012 Feb;120(1):38-45. doi: 10.1111/j.1600-0722.2011.00920.x. Epub 2012 Jan 23.

PMID:
22288919
30.

The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues.

Tel J, Hato SV, Torensma R, Buschow SI, Figdor CG, Lesterhuis WJ, de Vries IJ.

Cancer Immunol Immunother. 2012 Jul;61(7):1101-11. doi: 10.1007/s00262-011-1189-x. Epub 2011 Dec 23.

31.

Cytokine profiles in cyst fluids from ovarian tumors reflect immunosuppressive state of the tumor.

Yigit R, Massuger LF, Zusterzeel PL, Pots J, Figdor CG, Torensma R.

Int J Gynecol Cancer. 2011 Oct;21(7):1241-7. doi: 10.1097/IGC.0b013e3182289ab1.

PMID:
21946293
32.

Preferential recruitment of bone marrow-derived cells to rat palatal wounds but not to skin wounds.

Verstappen J, van Rheden RE, Katsaros C, Torensma R, Von den Hoff JW.

Arch Oral Biol. 2012 Jan;57(1):102-8. doi: 10.1016/j.archoralbio.2011.08.005. Epub 2011 Sep 3.

33.

Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination.

Mulder SF, Jacobs JF, Olde Nordkamp MA, Galama JM, Desar IM, Torensma R, Teerenstra S, Mulders PF, Vissers KC, Punt CJ, de Vries IJ, van Herpen CM.

Clin Cancer Res. 2011 Jul 1;17(13):4541-9. doi: 10.1158/1078-0432.CCR-11-0253. Epub 2011 Jun 28.

34.

Cytokine analysis as a tool to understand tumour-host interaction in ovarian cancer.

Yigit R, Figdor CG, Zusterzeel PL, Pots JM, Torensma R, Massuger LF.

Eur J Cancer. 2011 Aug;47(12):1883-9. doi: 10.1016/j.ejca.2011.03.026. Epub 2011 Apr 20.

PMID:
21514148
35.

Eradicating cancer cells: struggle with a chameleon.

Di J, Duiveman-de Boer T, Figdor CG, Torensma R.

Oncotarget. 2011 Jan-Feb;2(1-2):99-101.

36.

The recruitment of bone marrow-derived cells to skin wounds is independent of wound size.

Verstappen J, Katsaros C, Kuijpers-Jagtman AM, Torensma R, Von den Hoff JW.

Wound Repair Regen. 2011 Mar-Apr;19(2):260-7. doi: 10.1111/j.1524-475X.2011.00671.x.

PMID:
21362094
37.

Prophylactic vaccines mimic synthetic CpG oligonucleotides in their ability to modulate immune responses.

de Vries IJ, Tel J, Benitez-Ribas D, Torensma R, Figdor CG.

Mol Immunol. 2011 Mar;48(6-7):810-7. doi: 10.1016/j.molimm.2010.12.022. Epub 2011 Jan 22.

PMID:
21257206
38.

IL-4 and IL-13 alter plasmacytoid dendritic cell responsiveness to CpG DNA and herpes simplex virus-1.

Tel J, Torensma R, Figdor CG, de Vries IJ.

J Invest Dermatol. 2011 Apr;131(4):900-6. doi: 10.1038/jid.2010.410. Epub 2010 Dec 30.

39.

Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used.

Lesterhuis WJ, Schreibelt G, Scharenborg NM, Brouwer HM, Gerritsen MJ, Croockewit S, Coulie PG, Torensma R, Adema GJ, Figdor CG, de Vries IJ, Punt CJ.

Cancer Immunol Immunother. 2011 Feb;60(2):249-60. doi: 10.1007/s00262-010-0942-x. Epub 2010 Nov 11.

PMID:
21069321
40.

Skeletal muscle fibrosis: the effect of stromal-derived factor-1α-loaded collagen scaffolds.

Grefte S, Kuijpers-Jagtman AM, Torensma R, Von den Hoff JW.

Regen Med. 2010 Sep;5(5):737-47. doi: 10.2217/rme.10.69.

PMID:
20868329
41.

Bone marrow-derived cells in palatal wound healing.

Verstappen J, Katsaros C, Torensma R, Von den Hoff JW.

Oral Dis. 2010 Nov;16(8):788-94. doi: 10.1111/j.1601-0825.2010.01689.x.

PMID:
20561221
42.

Toll-like receptor triggering in cord blood mesenchymal stem cells.

van den Berk LC, Jansen BJ, Siebers-Vermeulen KG, Netea MG, Latuhihin T, Bergevoet S, Raymakers RA, Kögler G, Figdor CC, Adema GJ, Torensma R.

J Cell Mol Med. 2009 Sep;13(9B):3415-26. doi: 10.1111/j.1582-4934.2009.00653.x.

43.

Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro.

Cruz LJ, Tacken PJ, Fokkink R, Joosten B, Stuart MC, Albericio F, Torensma R, Figdor CG.

J Control Release. 2010 Jun 1;144(2):118-26. doi: 10.1016/j.jconrel.2010.02.013. Epub 2010 Feb 13.

PMID:
20156497
44.

Hematopoietic stem cells are coordinated by the molecular cues of the endosteal niche.

ter Huurne M, Figdor CG, Torensma R.

Stem Cells Dev. 2010 Aug;19(8):1131-41. doi: 10.1089/scd.2010.0038. Review.

PMID:
20148648
45.

Ovarian cancer creates a suppressive microenvironment to escape immune elimination.

Yigit R, Massuger LF, Figdor CG, Torensma R.

Gynecol Oncol. 2010 May;117(2):366-72. doi: 10.1016/j.ygyno.2010.01.019. Epub 2010 Feb 9. Review.

PMID:
20144842
46.

Model for muscle regeneration around fibrotic lesions in recurrent strain injuries.

Grefte S, Kuijpers-Jagtman AM, Torensma R, Von den Hoff JW.

Med Sci Sports Exerc. 2010 Apr;42(4):813-9. doi: 10.1249/MSS.0b013e3181beeb52.

PMID:
19952834
47.

Cord blood mesenchymal stem cells propel human dendritic cells to an intermediate maturation state and boost interleukin-12 production by mature dendritic cells.

van den Berk LC, Roelofs H, Huijs T, Siebers-Vermeulen KG, Raymakers RA, Kögler G, Figdor CG, Torensma R.

Immunology. 2009 Dec;128(4):564-72. doi: 10.1111/j.1365-2567.2009.03142.x.

48.

Mesenchymal stem cells respond to TNF but do not produce TNF.

van den Berk LC, Jansen BJ, Siebers-Vermeulen KG, Roelofs H, Figdor CG, Adema GJ, Torensma R.

J Leukoc Biol. 2010 Feb;87(2):283-9. doi: 10.1189/jlb.0709467. Epub 2009 Nov 6.

PMID:
19897767
49.

Functional differences between mesenchymal stem cell populations are reflected by their transcriptome.

Jansen BJ, Gilissen C, Roelofs H, Schaap-Oziemlak A, Veltman JA, Raymakers RA, Jansen JH, Kögler G, Figdor CG, Torensma R, Adema GJ.

Stem Cells Dev. 2010 Apr;19(4):481-90. doi: 10.1089/scd.2009.0288.

PMID:
19788395
50.

A functional model for adult stem cells in epithelial tissues.

Verstappen J, Katsaros C, Torensma R, Von den Hoff JW.

Wound Repair Regen. 2009 May-Jun;17(3):296-305. doi: 10.1111/j.1524-475X.2009.00497.x. Review.

PMID:
19660036

Supplemental Content

Loading ...
Support Center